Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Research & Development (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Research & Development for 10 consecutive years, with $203.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 8.18% to $203.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $750.0 million, a 7.45% increase, with the full-year FY2025 number at $750.0 million, up 7.45% from a year prior.
  • Research & Development was $203.3 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $216.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $237.3 million in Q3 2022 to a low of $113.2 million in Q2 2021.
  • A 5-year average of $164.9 million and a median of $164.8 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 490.07% in 2021, then plummeted 33.73% in 2023.
  • Ultragenyx Pharmaceutical's Research & Development stood at $123.0 million in 2021, then surged by 38.85% to $170.8 million in 2022, then dropped by 6.26% to $160.1 million in 2023, then increased by 17.36% to $187.9 million in 2024, then rose by 8.18% to $203.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Research & Development are $203.3 million (Q4 2025), $216.2 million (Q3 2025), and $164.7 million (Q2 2025).